比较英夫利昔单抗和阿达木单抗对炎症性肠病女性妊娠结局的安全性：系统评价与荟萃分析。
Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.
机构信息
Department of gynecology and obstetrics, Women's Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, Zhejiang Province, P.R. China.
Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, 310006, Hangzhou, Zhejiang Province, P.R. China.
出版信息
BMC Pregnancy Childbirth. 2022 Nov 19;22(1):854. doi: 10.1186/s12884-022-05191-z.
BACKGROUND
Inflammatory bowel disease (IBD) is a condition that affects most of the digestive tract. There is no report of fertility reduction in medically managed IBD women compared with the general population. On the other hand, active IBD can lead to significantly decreased fertility. Over the previous 2 decades, anti-tumor necrosis factor (anti-TNF) has been an effective treatment for managing patients with IBD, increasing the use of infliximab and adalimumab in clinical practice. However, it is unclear which biologics are better for pregnant women with IBD.
AIM
We conducted a systematic review and meta-analysis for the risk of adverse pregnancy outcomes following treatment with infliximab and adalimumab in women with IBD.
METHODS
Bibliographic databases were retrieved from their inception to July 2022. The results were adverse pregnancy outcomes, including congenital malformations and spontaneous abortion.
RESULTS
A total of 8 studies included 527 pregnant women with IBD. Of these, 343 received infliximab, and 184 received adalimumab therapy. Compared to adalimumab, adverse pregnancy outcomes were not increased in infliximab therapy including congenital malformations and spontaneous abortion.
CONCLUSION
Infliximab and adalimumab therapy did not show the difference of risk in adverse pregnancy outcomes in women with IBD.
SYSTEMATIC REVIEW REGISTRATION
http://www.crd.york.ac.uk/PROSPERO , identifier: CRD 42,021,277,869.
背景
炎症性肠病（IBD）是一种影响大部分消化道的疾病。与普通人群相比，经医学管理的 IBD 女性的生育力没有降低的报道。另一方面，活动期 IBD 可导致生育力显著下降。在过去的 20 年中，抗肿瘤坏死因子（抗 TNF）已成为治疗 IBD 患者的有效方法，使英夫利昔单抗和阿达木单抗在临床实践中的应用增加。然而，尚不清楚哪种生物制剂对患有 IBD 的孕妇更有效。
目的
我们进行了一项系统评价和荟萃分析，以评估 IBD 女性接受英夫利昔单抗和阿达木单抗治疗后的不良妊娠结局风险。
方法
从其成立到 2022 年 7 月，检索了文献数据库。结果是不良妊娠结局，包括先天性畸形和自然流产。
结果
共有 8 项研究纳入了 527 名患有 IBD 的孕妇。其中，343 名接受了英夫利昔单抗治疗，184 名接受了阿达木单抗治疗。与阿达木单抗相比，英夫利昔单抗治疗的不良妊娠结局（包括先天性畸形和自然流产）并未增加。
结论
英夫利昔单抗和阿达木单抗治疗在 IBD 女性中的不良妊娠结局风险没有差异。
系统评价注册
http://www.crd.york.ac.uk/PROSPERO ，标识符：CRD42,021,277,869。
Zotero 插件